Improved determination of Neisseria gonorrhoeae gyrase A genotype results in clinical specimens.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
07
03
2019
revised:
03
06
2019
accepted:
07
06
2019
pubmed:
25
7
2019
medline:
16
7
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
The emergence of drug-resistant Neisseria gonorrhoeae has prompted the development of rapid molecular assays designed to determine antimicrobial susceptibility. One common assay uses high-resolution melt analysis to target codon 91 of the gyrase A gene (gyrA) to predict N. gonorrhoeae susceptibility to ciprofloxacin. We extracted DNA from remnant clinical specimens that had previously tested positive for N. gonorrhoeae using the Aptima Combo 2 for CT/NG assay (Hologic, San Diego, CA, USA). We selected DNA extracts from specimens with indeterminate, WT and mutant gyrA genotype results from a previous study using high-resolution melt analysis to detect the gyrA codon 91 mutation. We re-tested those specimens using the recently CE-marked ResistancePlus GC (beta) assay (SpeeDx, Sydney, Australia). Of 86 specimens with indeterminate gyrA genotypes on high-resolution melt analysis, the ResistancePlus GC (beta) assay (SpeeDx) identified 30 (35%) WT, 22 (26%) mutant and 34 (40%) indeterminate gyrA genotypes. The ResistancePlus GC (beta) assay showed improved N. gonorrhoeae gyrA genotype determination compared with a prior gyrA genotypic high-resolution melt assay.
Sections du résumé
BACKGROUND
The emergence of drug-resistant Neisseria gonorrhoeae has prompted the development of rapid molecular assays designed to determine antimicrobial susceptibility. One common assay uses high-resolution melt analysis to target codon 91 of the gyrase A gene (gyrA) to predict N. gonorrhoeae susceptibility to ciprofloxacin.
METHODS
We extracted DNA from remnant clinical specimens that had previously tested positive for N. gonorrhoeae using the Aptima Combo 2 for CT/NG assay (Hologic, San Diego, CA, USA). We selected DNA extracts from specimens with indeterminate, WT and mutant gyrA genotype results from a previous study using high-resolution melt analysis to detect the gyrA codon 91 mutation. We re-tested those specimens using the recently CE-marked ResistancePlus GC (beta) assay (SpeeDx, Sydney, Australia).
RESULTS
Of 86 specimens with indeterminate gyrA genotypes on high-resolution melt analysis, the ResistancePlus GC (beta) assay (SpeeDx) identified 30 (35%) WT, 22 (26%) mutant and 34 (40%) indeterminate gyrA genotypes.
CONCLUSIONS
The ResistancePlus GC (beta) assay showed improved N. gonorrhoeae gyrA genotype determination compared with a prior gyrA genotypic high-resolution melt assay.
Identifiants
pubmed: 31340021
pii: 5537992
doi: 10.1093/jac/dkz292
pmc: PMC8420954
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ciprofloxacin
5E8K9I0O4U
DNA Gyrase
EC 5.99.1.3
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2913-2915Subventions
Organisme : NIAID NIH HHS
ID : R21 AI109005
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Curr Opin Infect Dis. 2016 Feb;29(1):45-51
pubmed: 26658656
J Antimicrob Chemother. 2015 Feb;70(2):374-81
pubmed: 25331059
MMWR Surveill Summ. 2016 Jul 15;65(7):1-19
pubmed: 27414503
J Clin Microbiol. 2016 Mar;54(3):805-8
pubmed: 26739156
Clin Infect Dis. 2017 May 1;64(9):1268-1270
pubmed: 28034887
Ann Intern Med. 2008 Apr 15;148(8):606-13
pubmed: 18413622
PLoS One. 2017 Jan 23;12(1):e0170087
pubmed: 28114309
Sex Transm Dis. 2017 May;44(5):261-265
pubmed: 28407640
Sex Transm Dis. 2018 Feb;45(2):87-91
pubmed: 29329176
Future Microbiol. 2012 Dec;7(12):1401-22
pubmed: 23231489
J Antimicrob Chemother. 2019 Jul 1;74(7):1820-1824
pubmed: 30897201
JAMA. 2013 Jan 9;309(2):163-70
pubmed: 23299608